Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306135 · ClinicalTrials.gov registry record
Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT02306135 is a clinical trial that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT02306135 was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation, and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric inhibitor of mTOR that suppresses mTORC1 activity. Everolimus is FDA-approved for the treatment of ER+/HER2- breast cancer (in combination with exemestane), renal cell carcinoma, subependymal giant cell astrocytoma (SEGA), and neuroendocrine tumors of pancreatic origin (PNET), and is currently being tested in ongoing clinical studies in other indications. While everolimus-based therapies elicit anti-cancer effects, most cancers ultimately progress and exhibit everolimus resistance. This study will evaluate genetic mechanisms of resistance to everolimus.
Interventions
- OTHER n/a- this is an observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02306135
The ClinicalTrials.gov registry entry for NCT02306135 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which n/a- this is an observational study is the first listed.
NCT02306135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02306135 about?
NCT02306135 is a clinical study titled "Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer". mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation, and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric inhibitor of mTOR that suppresses mTORC1 activity. Everolimus is FDA-approved for the treatment of ER+/HER2- breast can...
What is the current status of trial NCT02306135?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2015-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02306135?
The interventions under investigation include: n/a- this is an observational study (OTHER).
Who is sponsoring clinical trial NCT02306135?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.